ÀüÈ«Àç
¾Ï¼¾ÅÍÀå
¼Ò
¼Ó
: ºÐ´çÂ÷º´¿ø
Àü¹®ºÐ¾ß : °£¾Ï/Ãé´ãµµ¾Ï
Á÷
ˤ
: ºÎ±³¼ö(¾Ï¼¾ÅÍÀå)
¸Þ
ÀÏ
:
ºñ°ø°³
Àü
È
:
1577-4488
ÆÑ
½º
:
ÁÖ
¼Ò
:
°æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßžµ¿ 351¹øÁö
ȨÆäÀÌÁö:
ÅǸ޴º
ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£
±¸ºÐ
Á¦¸ñ
´Ù¿î·Îµå
15
ÇØ¿Ü
Anticancer adjuvant composition comprising liposome and the method of drug delivery using the same (10-2019-0151619. 209)
14
ÇØ¿Ü
Prognostic Implications of PD-L1 Expression in Patients with Soft Tissue Sarcoma. BMC Cancer 2016 (IF 3.265)
13
ÇØ¿Ü
Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients. BMC Cancer 2016 (IF 3.265)
12
ÇØ¿Ü
Rho GTPase RhoJ is associated with gastric cancer progression and metastasis. J Cancer 2016 (IF 3.609)
11
ÇØ¿Ü
Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy. J Breast Cancer 2016
10
ÇØ¿Ü
Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma. Annals of Surgery 2016
9
ÇØ¿Ü
The Clinicopathological Features and Prognostic Impact of ALK-positivity in Resected Gastric Cancer Patients.Annals of Surgical Oncology 2015
8
ÇØ¿Ü
Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane
7
ÇØ¿Ü
Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer
6
±¹³»
A case of nephrogenic systemic fibrosis after gadolinium-based contrast agent injection.
1
2
3
4
5
6
7
8
Copyright ¨Ï chamc, All rights reserved.
ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à
Àüȹ®ÀÇ
°³²Â÷º´¿ø 02.3468.3000
ºÐ´çÂ÷º´¿ø 031.780.5000
Â÷¿ò 02.3015.5300
±¸¹ÌÂ÷º´¿ø 054.450.9700
´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
°³²°ÇÁø¼¾ÅÍ 02.2191.3900
ºÐ´çÁ¾ÇÕ°Ç°ÁõÁø¼¾ÅÍ 031.780.5940
½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729